Keep up to date with our latest partnering deals and highlights

Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.

Wednesday, 11 September 2013
AstraZeneca and Merck enter licence agreement for investigational oral WEE1 kinase inhibitor therapy for cancer AstraZeneca and Merck & Co Inc , known outside the United States and Canada as MSD, today announced a worldwide licensing agreement.
Monday, 26 August 2013
MedImmune strengthens immune-mediated cancer therapy portfolio with acquisition of Amplimmune AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune
Wednesday, 31 July 2013
AstraZeneca and FibroGen collaborate to develop and commercialise FG-4592, a treatment for anaemia in chronic kidney disease and end-stage renal disease Collaboration to include US, China and selected other markets
Download our brochure

Download your comprehensive guide to partnering with us.

Meet us at an event

Calendar iconView our full event calendar to see events we are attending.

View calendar